Miriam Mwachinga: Let’s Focus More on Rare Diseases and Their Impact on Quality of Life
Miriam Mwachinga, General Practitioner, Internal Medicine, Medical Affairs at Healthcare Industry, Pharmaceutical Ind, shared on LinkedIn:
”One of my college professors once made a comment that has stayed with me over the years.
Diseases that affect 1 in a million often seem insignificant, but the impact on your quality of life if you are that 1 person in a million is huge.
Rare diseases tend to be overlooked because the cost: benefit ratio doesn’t make economic sense when it comes to drug development, but that doesn’t make them any less significant.
Hemophilia A is the most common genetic X-linked disease, but still far behind when it comes to clinical research.
With Rare Disease Day coming up later this month, let’s all focus a bit more on rare diseases.”
Stay updated with Hemostasis Today.
-
Feb 12, 2026, 11:32Sophie Titoulet Announces Challenge Plasma 2026: The Art of Giving Regularly
-
Feb 12, 2026, 11:19Goran Mitulović: Proteomics and Mass Spectroscopy Identified The Cause of VITT
-
Feb 12, 2026, 11:14Leonardo Roever: CHR as a Composite Biomarker for Stroke Risk Stratification
-
Feb 12, 2026, 11:10Filippo Cademartiri: Can AI Reduce Diagnostic Errors in Low-Resource Settings?
-
Feb 12, 2026, 11:06Murad Ali: An Important Marker of Active Clot Formation and Fibrinolysis
-
Feb 12, 2026, 11:02Right Chukwuneme: Daltaparin vs Apixaban – Efficacy or Safety Paradox?
-
Feb 12, 2026, 10:57Muntadhar Al Moosawi Gives A Talk on Chromogenic FVIII in Hemophilia A at WHX Labs Dubai
-
Feb 12, 2026, 10:52Dario Bongiovanni: Meeting Wrap-Up of ESC Heart and Stroke and EuroThrombosis 2025
-
Feb 12, 2026, 10:40Nikolaos Kotsiou: Honored to Represent the Hemophilia Center of Northern Greece at EAHAD 2026